



Total Heart Intelligence... Wherever You Are

ADVANCED CARDIAC INTELLIGENCE PLATFORM | 25 PATENTS | FDA CLEARED

INVESTOR PRESENTATION March 12, 2026



Investor Presentation 2026

NASDAQ : BEAT

Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of management for future operations, are forward-looking statements.

These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.


In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "aims," "predicts," "potential," "seeks," attempts," "poised" or "continues" or the negative of these terms or other similar words. These statements are only predictions.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other industry data. This data involves several assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness.

In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by independent parties and by the Company. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see disclosures contained in HeartBeam's public filings with the SEC, including the "Risk Factors" in HeartBeam's Annual Report on Form 10-K, and which may be viewed at www.sec.gov.

The HeartBeam System received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company's Cleared Indications for Use at <https://www.heartbeam.com/indications> for details on the intended use of its technology.

A photograph of a hospital room. In the foreground, a gurney with a white sheet and pillow is positioned horizontally. To the left, a medical cart holds a monitor displaying a waveform. The background wall is equipped with various medical supplies, including bags and tubes hanging from a rack. A grey trash can stands near a counter with cabinets on the right. A television is mounted on the wall in the upper right corner.

THE GAP IN CARDIAC DETECTION

Heart attack detection requires 12-Lead ECG data, which is **primarily available in clinical settings.**

Consumer and wearable ECG devices do not provide sufficient spatial orientation for ischemia detection. As a result, clinicians lack reliable data when symptoms occur outside the hospital.

Patient Delay is the Major Driver Behind the #1 Cause of Death

Treatment time in hospital is optimized. Patient delay happens before arrival.



Patients Delay 3+ Hours Before Taking Action

Uncertainty Delays Action

PATIENT OUTCOME

Every 30 Minute Delay Increases:

8.7% ▲
Heart failure risk

7.5% ▲
1-year mortality

COSTLY COMPLICATIONS

Heart failure drives:

\$30,000
annual cost per patient

5-year avg.
life expectancy

Decision to call 911

Treatment Time is Optimized Once the Patient Reaches the Hospital

Rapid 12-Lead ECG in guidelines



Rapid EMS activation and transport



Streamlined emergency room triage



Immediate stenting with door-to-balloon time under 90 minutes


There is no dependable solution to reduce this pre-hospital delay.
Current at-home ECG tools cannot reliably detect heart attacks.

HeartBeam Brings a Clinical-Grade 12-Lead ECG Into the Home

BRINGING CARE BEYOND THE HOSPITAL

A Cardiac Intelligence Platform...Anywhere. Powered by FDA-cleared ECG technology.

HeartBeam is the **first ever cable-free, synthesized, 12-Lead ECG platform**, delivering clinical-grade insights in real time, wherever symptoms occur.



Using the Heartbeam System




[Click here to watch the demo video](#)



This Platform Addresses
Tens of Millions of Patients
Across Multiple Segments

CORE PLATFORM



**PATENTED 3D SIGNAL
COLLECTION TECHNOLOGY**

FORM FACTORS

**One platform.
Two form factors.
Shared cardiac
intelligence.**

**HEARTBEAM
SYSTEM**
CABLE-FREE 12-LEAD ECG
FOR AT-HOME USE



**ON-DEMAND
12-LEAD PATCH**
CONTINUOUS
1-LEAD → 12-LEAD
ON DEMAND



APPLICATIONS ENABLED

ARRHYTHMIA



**HEART ATTACK
DETECTION**




**PERSONALIZED AI
ALGORITHMS**



Fundamental Advances Covered by Over 20 Patents Enables HeartBeam's Unique Approach


Capturing the Heart's Signals in 3 Dimensions

Patented method that collects heart signals in three non-coplanar dimensions, capturing the full electrical activity of the heart.



Novel Form Factor

Proprietary resistive network enables a three-dimensional approach and a synthesized 12-Lead ECG, all in a credit card-sized device.



Clinically Accurate Conversion

Personalized algorithms convert signals from three non-coplanar dimensions into physician-ready 12-Lead ECG readouts in real time.



50M+ Patient, \$40B Cardiac Platform Opportunity

Scaling from direct-pay launch to large areas of clinical need

INITIAL MARKET ENTRY POINT


1.5M

PATIENTS
Concierge
& Preventive
Cardiology

EXPANSION OPPORTUNITY

3.5M

PATIENTS
Broader
Patient Pay –Telehealth,
Direct to Consumer



DATA:

i. 5.0+ million patients in Direct Patient Pay in U.S. (including 1.5M+ in Concierge Market and 3.5M+ in broader patient pay market) × \$750 per year per patient

ii. 20+ million patients in U.S. at risk of heart attack (8 million prior MI + 12 million at high risk) × \$750 per year per patient

iii. 260+ million adults in U.S. × ~20% either rhythm diagnosis, palpitations, or recurring unexplained cardiac symptoms reported at some point × \$750 per year per patient; \$750 per year per patient assumed as baseline until further validation of market opportunity

The HeartBeam System is FDA Cleared and Ready for Launch

HeartBeam System Cleared and Ready For Launch

**FDA 510(k) clearances for
arrhythmia detection:**


- ✓ 12/2024:
The HeartBeam System
- ✓ 12/2025:
12-Lead synthesis algorithm

- ✓ Strong IP:
25 Issued Patents Worldwide
- ✓ Robust Clinical Evidence:
14 Clinical Papers & Presentations



We Are Entering This Market Strategically

An Ideal Early Market: Concierge and Preventive Cardiology



Strong willingness to pay

1.5M+ Americans pay out of pocket for concierge medicine


Cardiovascular care becomes a **major healthcare spending category** beginning in midlife (ages 45–70), a core demographic for concierge medicine

Concierge and longevity programs cost an average of **\$3,000 to \$10,000 per year** with premium practices costing **\$50,000+**

HeartBeam pricing at **\$500 to \$1,000 per year per patient** is a **small fraction of current spend**


Targeting concierge and preventive cardiology enables premium pricing, controlled rollout, and early revenue generation

Evidence of demand



HIGH-NET-WORTH
INDIVIDUALS

Likely
to purchase




HIGH-NET-WORTH
INDIVIDUALS

Prefer premium
over basic tier



CONCIERGE
PATIENTS

Willing to pay more
than twice what non-
concierge high net
worth individuals
would pay



CONCIERGE
PHYSICIANS

Would
recommend to
their patients

Concierge and Preventive Cardiology: an Initial Market and a Sales Channel

Patients are demanding it.
Physicians want to offer it.

PATIENTS

Demand latest clinical
innovations and technology

Proven willingness to pay

Trust physician recommendations

HeartBeam provides the peace of mind
of at-home 12-Lead ECG +
on-call cardiologists



Patients actively seek
advanced technology



Physician-endorsed
recommendation

PHYSICIANS

Tech-forward early adopters

Desire to **differentiate** their practice

Enhance **relationship** with patients

HeartBeam offers 24/7 peace of mind
for patients and promotes proactive
care


An efficient sales process and rapid adoption: these practices work together with HeartBeam to sell to patients

Focused Launch. Foundation for Scale.

Proving success in Cardiology
and Executive Concierge Practices

**IMMEDIATE FOCUS
FOR LIMITED LAUNCH:
CARDIOLOGY AND EXECUTIVE CONCIERGE**

- Practice Size: 400–4,000 patients
- Concentrated in NY, South Florida, Dallas, Southern California
- Predominantly physician owned
- 10% of 1.5M Concierge Market
- Break-even achievable within this segment alone



Creates a Playbook to Accelerate Growth Nationwide

**ACCELERATING GROWTH:
NATIONAL CHAINS**

- Practice Size: 100,000-400,000 patients per network
- Leverage validated proof points from initial launch
- Standardize workflow and implementation at scale
- Utilize high HSA and FSA adoption
- Cost-effective expansion strategy doesn't require huge sales force

MDVIP

SignatureMD

CONCIERGE
CHOICEPHYSICIANS

Clear Plan to Fuel the Next Stage of Growth

Apply what HeartBeam learns in a focused approach to accelerate efficient expansion

1ST HALF 2026

Validate premium value proposition

Refine HeartBeam systems and processes

Sign and onboard anchor accounts

Prove scaling efficiency

2ND HALF 2026

Prove deep adoption into anchor accounts

Establish funnel to support 2027 revenue and adoption goals

Develop white papers/proof points for future adoption

Expand sales team for regional growth

2027+

Scale revenue

Move to a train-the-trainer model for implementation

Expand clinical research opportunities

Full commercial team onboard

SCALING EFFICIENTLY WITHOUT THE NEED FOR A LARGE FIELD FORCE

One sale to a practice → enroll many patients

Fulfill inbound patient demand from anchor accounts

No DTC marketing spend

HIGH-MARGIN, SUBSCRIPTION BUSINESS WITH PATH TO BREAK-EVEN

70%+ margins on recurring revenue

Only 3-5 month payback period to cover year 1 upfront costs

Cash flow break-even at ~30,000 patients




Commercial Partnership with ClearCardio, a key part of launch strategy



Partnering with leading cardiology and executive concierge practices that want to deeply adopt HeartBeam

- Has helped **thousands of patients** through advanced heart-health screening and personalized prevention programs.
- **Highly engaged, premium patient population** in Dallas and New York, **expanding** to additional locations
- Patients routinely undergo advanced imaging and ongoing cardiovascular monitoring — creating **strong alignment with HeartBeam's at-home, 12-Lead ECG capability for arrhythmia assessment.**
- Potential to drive deep adoption and make HeartBeam accessible to thousands of active patients within the practice over time.



HEARTBEAM INITIAL LAUNCH STRATEGY

SIGN LEADING PRACTICES THAT WANT DEEP HEARTBEAM UTILIZATION

ClearCardio

Exec Health Practice

Exec Health Practice

PARTNER CLOSELY TO DRIVE PATIENT ADOPTION AND ENGAGEMENT



CAPTURE EXPERIENCES AND PROOF POINTS AS WE EXPAND TO MORE PRACTICES



Practice

Practice

Practice

Practice

Practice



Practice

Practice

Practice

Practice

Practice

Commercial Launch is Only the Beginning

Heart Attack Detection

Clinical-grade heart attack detection, available wherever patients are.

20M+ high-risk patients in the U.S.

Problem

Patients can't recognize a heart attack at home

12-Lead ECG is only in hospitals

3–4 hour delays = death or heart failure

Why We Win

Two proof of concept studies show HeartBeam is similar to standard 12-Lead ECG

Baseline ECG improves accuracy over single ECG

Same device → expanded indication (no new hardware)

Same device. Expanded indication.

Heart Attack Detection: Clinical Validation Underway

We are rapidly advancing clinical validation to support indication expansion into acute ischemia / heart attack detection.



Existing proof-of-concept studies demonstrate high concordance to standard 12-Lead ECGs

- Novel 3D approach captures the full 12-Lead ECG information set — no need for 12-Lead synthesis
- Comparison to patient baseline shown to further increase accuracy

Pilot study underway in patients presenting with chest pain in the Emergency Department

- ED design accelerates timelines (not prescribing to patients and waiting for events)
- Evaluating HeartBeam 3D ECG and standard 12-Lead ECG vs. discharge diagnosis
- Informs pivotal study design

HeartBeam AI Uniquely Brings 12-Lead Personalized Insights to Patients at Home

12-Lead ECG AI exists today, but only in clinical settings. HeartBeam enables longitudinal 12-Lead insights at home.

12-Lead ECG + AI Today

CLINICALLY PROVEN ACROSS:

- Arrhythmias
- Structural Heart issues
- Heart Failure
- And more



HeartBeam's Differentiation

- Synthesized 12-Lead ECG at home
- Longitudinal, repeatable data collection
- AI evaluation over time, not just snapshots



DRIVERS:

- More personalized risk estimate
- Earlier identification of cardiac conditions
- Greater predictive power

Expands beyond arrhythmia and heart attack

Enables disease prediction and ongoing management

Opens new TAM

Supports new clinical indications

Creates potential new reimbursement pathways



Mt. Sinai Partnership

HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

Accelerates development of personalized cardiac AI algorithms on the HeartBeam platform across wellness and clinical use cases including assessing heart attack risk.

Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management.

Combines Mount Sinai's world-class AI-ECG expertise and clinical expertise with HeartBeam's world-class AI-ECG team and its groundbreaking 3D ECG signal collection technology.

HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere over time – extending access beyond traditional clinical settings



The Platform Extends Across Form Factors

HeartBeam's On-Demand 12-Lead Patch: Disrupting the Patch Market

TODAY'S PATCH MARKET

Patch monitors are a \$2B revenue market with existing reimbursement

Devices are 1-3 leads, which limit applications to arrhythmia detection and monitoring

Mobile Cardiac Telemetry (MCT) segment has highest reimbursement and fastest growth



HEARTBEAM ON-DEMAND 12-LEAD PATCH

Development of Working Prototype of Patch complete

Clinical grade 12-Lead ECG in a patch form factor

Continuous 1-Lead mode matches performance of existing systems

On-demand 12-Lead ECG mode **expands segment into ischemia detection**

Integrates into **existing clinical workflow**

Leverages existing **MCT reimbursement**

Ability to drive market share shifts and grow the market

Investor Presentation 2026




<https://www.reanin.com/reports/electrocardiograms-patch-and-holter-monitor-market>
<https://www.gminsights.com/pressrelease/wearable-cardiac-devices-market>
12-Lead patch product not cleared by FDA and not available for sale in the United States or other geographies.


HeartBeam's 12-Lead Technology Fills Key Gaps, Draws Strong Physician Demand

PHYSICIANS WANT TO SWITCH TO 12-LEAD PATCH

PHYSICIANS THAT CURRENTLY PRESCRIBE PATCH MONITORS




Of physicians would switch a portion of patients to a 12-Lead patch



Of existing patients that physicians would switch

FOR USE CASES, WHERE MDs PRESCRIBE OTHER CARDIAC MONITORING TECHNOLOGIES (e.g. HOLTER)




Of physicians would switch a portion of patients to a 12-Lead patch




PHYSICIANS WILL PRESCRIBE MORE (MARKET ACTUALLY GROWS)

FOR USE CASES, WHERE MDs DO NOT PRESCRIBE CARDIAC MONITORING TECHNOLOGY



Of physicians would increase their patch utilization



AVERAGE increase in utilization



Unveiling HeartBeam's 12-Lead ECG Patch

For demo purposes only. HeartBeam's 12-Lead ECG Patch is not FDA cleared and not available for sale anywhere in the world.

©HeartBeam, Inc. All rights reserved. March 2026.



[Click here to watch the video](#)



Building Long-Term Value

Upcoming Milestones

Continued progress on commercialization and other major corporate initiatives

	Q1 26	Q2 26	Q3 26	Q4 26	2027-
12-LEAD LIMITED LAUNCH 	✓ 12-LEAD FDA CLEARANCE ✓ CCO HIRE	VALIDATE PREMIUM POSITIONING SIGN/ONBOARD INITIAL ACCOUNTS	ESTABLISH FUNNEL FOR 2027 GOALS DEVELOP PROOF POINTS FOR ADOPTION EXPAND COMMERCIAL TEAM		SCALE REVENUE FURTHER EXPAND TEAM
HEART ATTACK DETECTION 	✓ INITIATE ALIGN-ACS STUDY	INITIATE HEADSTART-ACS STUDY	COMPLETE ALIGN-ACS FINALIZE FDA PIVOTAL STUDY DESIGN		CONDUCT ALIGN-ACS II PIVOTAL STUDY
12-LEAD PATCH 	✓ COMPLETE DEVELOPMENT OF PATCH WORKING PROTOTYPE	PARTNERSHIP DISCUSSIONS		COLLABORATE ON CLINICAL AND REGULATORY PATHWAY	
ARTIFICIAL INTELLIGENCE 	✓ FINALIZE MT SINAI COLLABORATION	DEVELOP AI WELLNESS AND MI DETECTION MODELS		FDA CLEARANCE OF ARRHYTHMIA ALGORITHM	DELIVER ADDITIONAL ALGORITHMS

Financials

Financial Discipline Aligned to Achieving Milestones

- Net cash used in operating activities of \$14.0M in 2025, including just \$2.9M in Q4 2025.
 - **30% decrease compared to same quarter prior year.**
 - 3% decrease year-over-year.

Net cash used in operating activities (\$000s)	Q1	Q2	Q3	Q4	2025
	\$ (4,477)	\$ (3,445)	\$ (3,160)	\$ (2,906)	\$ (13,988)
Quarter-over-Quarter Change	8%	-23%	-8%	-8%	
Year-over-Year Change	29%	-3%	-4%	-30%	-3%

- **Spend and EPS directly in line with expectations.**
- Continued focus on maintaining capital efficient organization.
- Judicious timing of investments into key growth initiatives.
- Operating cash outflow expected to be \$17.0M–\$19.0M in 2026, before factoring in cash receipts from customers.
- **Continue to strategically fund Company.**
 - Strong financial discipline in place as we continue to de-risk business.
 - Optionality for funding sources, including ATM.
 - Focused on minimizing further dilution to shareholders.

	YEAR-OVER-YEAR QUARTERLY CHANGE		YEAR-OVER-YEAR ANNUAL CHANGE	
	Quarter Ended December 31,		Year Ended December 31,	
\$ in Thousands	2025 ⁱⁱⁱ	2024	2025 ⁱⁱⁱ	2024
Operating Expenses:				
General and administrative	\$ 1,956	\$ 2,058	\$ 7,689	\$ 8,836
Research and development	3,354	2,886	13,450	11,051
Total operating expenses	5,310	4,944	21,139	19,887
Loss from operations	(5,310)	(4,944)	(21,139)	(19,887)
Interest and other expense (net)	8	37	124	439
Net Loss	\$ (5,302)	\$ (4,907)	\$ (21,015)	\$ (19,448)
Earnings per Share (EPS)	\$ (0.15)	\$ (0.18)	\$ (0.62)	\$ (0.73)
Net Loss	\$ (5,302)	\$ (4,907)	\$ (21,015)	\$ (19,448)
Less non-cash items and timing differences	2,396	755	7,027	4,977
Net cash used in operating activitiesⁱ	\$ (2,906)	\$ (4,152)	\$ (13,988)	\$ (14,471)
	2025 ⁱⁱⁱ	2024	2025 ⁱⁱⁱ	2024
Cash, cash equivalents and restricted cashⁱⁱ	\$ 4,436	\$ 2,433	\$ 4,436	\$ 2,433

i. Net cash used in operating activities is calculated as Net loss, less non-cash items such as stock-based compensation and timing differences.

ii. Includes restricted cash of \$56k for December 31, 2025.

iii. Refer to the Form 10-K audited financial statements for the year ended December 31, 2025.

Summary

Executing on a \$40B Cardiac Monitoring Platform Opportunity

- Ability to serve 50M+ patients across multiple applications and form factors
- Continued execution across key growth initiatives
- Multiple value creation opportunities in 2026
- Capital-efficient strategy; judicious timing of investments

Significantly De-Risked

- First ever FDA-cleared, cable-free synthesized 12-Lead ECG to use anytime, anywhere for arrhythmia assessment
- Strong IP and Clinical Evidence

Limited Commercial Launch

- Commencing launch of cable-free, synthesized 12-Lead ECG
- Cost-effective expansion strategy does not require huge sales force

Heart Attack Detection

- Rapidly advancing clinical validation to support indication expansion into acute ischemia/heart attack detection

Partnership Opportunities

- Collaborate with strategic partners on clinical and regulatory pathway for extended wear 12-Lead ECG Patch
- Partner with leading institutions in AI



Our Team

Leadership Team



ROB ENO

Chief Executive Officer



BRANISLAV VAJDIC, PHD

Founder & President



TIM CRUICKSHANK

Chief Financial Officer



BRYAN HUMBARGER

Chief Commercial Officer



CHRIS ACHAR

Head of Strategy
Synergy Ventures




KEN PERSEN

Chief Technology Officer




LANCE MYERS

Chief AI Scientist



RICHA GUJARATI

SVP, Product




DEBORAH CASTILLO, PHD

VP, Regulatory



POOJA CHATERJEE

VP, Clinical



Scientific Advisory Board



PETER FITZGERALD, MD, PHD
Chief Medical Advisor



C. MICHAEL GIBSON, MD
SAB Chair



ROBERT HARRINGTON, MD
SAB Member



CHARLES L. BROWN III, MD
SAB Member



TONY DAS, MD
SAB Member



CAMPBELL ROGERS, MD
SAB Member



NIRAJ VARMA, MD, PHD
SAB Member



VIVEK Y. REDDY, MD
SAB Member



HeartBeam Board of Directors



RICH FERRARI
Executive Chairman



BRANISLAV VAJDIC, PHD
Founder & President



MARGA ORTIGAS-WEDEKIND
Board Member



WIM ELFRINK
Board Member



GEORGE DE URIOSTE
Board Member



KENNETH NELSON
Board Member



MARK STROME
Board Member



MICHAEL JAFF, DO
Board Member



ROB ENO
Chief Executive Officer





NASDAQ: BEAT

Redefining Cardiac Care Anytime, Anywhere.

Company

Tim Cruickshank

CFO

HeartBeam, Inc.

ir@heartbeam.com

www.heartbeam.com

Investor Relations

Chris Tyson

Executive Vice President

MZ North America

Direct: 949-491-8235

BEAT@mzgroup.us

www.mzgroup.us